1563175-17-6

Basic information

• Product Name: N6-(2-(4-([1,1′-biphenyl]-4-yl)piperazin-1-yl)ethyl)-N6-propyl-5,6,7,8-tetrahydroquinazoline-2,6-diamine
• Synonyms: N6-(2-(4-([1,1′-biphenyl]-4-yl)piperazin-1-yl)ethyl)-N6-propyl-5,6,7,8-tetrahydroquinazoline-2,6-diamine
• CAS NO: 1563175-17-6
• Molecular Weight: 470.661
• Mol File: 1563175-17-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N6-(2-(4-([1,1′-biphenyl]-4-yl)piperazin-1-yl)ethyl)-N6-propyl-5,6,7,8-tetrahydroquinazoline-2,6-diamine(CAS DataBase Reference)
• NIST Chemistry Reference: N6-(2-(4-([1,1′-biphenyl]-4-yl)piperazin-1-yl)ethyl)-N6-propyl-5,6,7,8-tetrahydroquinazoline-2,6-diamine(1563175-17-6)
• EPA Substance Registry System: N6-(2-(4-([1,1′-biphenyl]-4-yl)piperazin-1-yl)ethyl)-N6-propyl-5,6,7,8-tetrahydroquinazoline-2,6-diamine(1563175-17-6)

Safety Data

• Hazardous Substances Data: 1563175-17-6(Hazardous Substances Data)

Upstream product

• 681482-18-8 t-butyl 4-([1,1′-biphenyl]-4-yl)piperazine-1-carboxylate 
• 92-54-6 4-phenyl-1-piperazine 
• 96530-59-5 1-(piperazin-1-yl)-4-iodobenzene 
• 1563175-08-5 N-(2-(4-([1,1′-biphenyl]-4-yl)piperazin-1-yl)ethyl)-N-propyl-1,4-dioxaspiro[4.5]decan-8-amine 
• 1563175-32-5 2-(4-([1,1′-biphenyl]-4-yl)piperazin-1-yl)acetaldehyde 
• 944678-48-2 2-(4-([1,1′-biphenyl]-4-yl)piperazin-1-yl)ethanol 
• 151978-66-4 tert-butyl 4-(4-iodophenyl)tetrahydro-1(2H)-pyrazinecarboxylate 
• 1563175-22-3 1-([1,1′-biphenyl]-4-yl)-4-(2-((tert-butyldimethylsilyl)oxy)ethyl)piperazine 
• 180698-19-5 1-(1,1′-biphenyl-4-yl)piperazine 
• 1563175-15-4 4-((2-(4-([1,1′-biphenyl]-4-yl)piperazin-1-yl)ethyl)(propyl)amino)cyclohexanone 
• 124-46-9 guanidine hydrogen carbonate 

Relevant articles and documents

Structural modifications of neuroprotective anti-parkinsonian (-)-N6-(2-(4-(biphenyl-4-yl)piperazin-1-yl)-ethyl)-N6-propyl-4,5,6, 7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264): An effort toward the improvement of in vivo efficacy of the parent molecule

In our overall goal to develop multifunctional dopamine D 2/D3 agonist drugs for the treatment of Parkinson's disease (PD), we previously synthesized potent D3 preferring agonist D-264 (1a), which exhibited neuroprotective properties in two animal models of PD. To enhance the in vivo efficacy of 1a, a structure-activity relationship study was carried out. Competitive binding and [35S]GTPγS functional assays identified compound (-)-9b as one of the lead molecules with preferential D3 agonist activity (EC50(GTPγS); D3 = 0.10 nM; D2/D3 (EC50): 159). Compounds (-)-9b and (-)-8b exhibited high in vivo activity in two PD animal models, reserpinized and 6-hydroxydopamine (OHDA)-induced unilateral lesioned rats. On the other hand, 1a failed to show any in vivo activity in these models unless the compound was dissolved in 5-10% beta-hydroxy propyl cyclodextrin solution. Lead compounds exhibited appreciable radical scavenging activity. In vitro experiments with dopaminergic MN9D cells indicated neuroprotection by both 1a and (-)-9b from toxicity of MPP+.